816 filings
Page 5 of 41
S-8
ucrd zume
18 Jan 22
Registration of securities for employees
5:12pm
8-K
lop319h8lr u8i5nx1v6
10 Jan 22
Departure of Directors or Certain Officers
4:28pm
EFFECT
4bn417v
28 Dec 21
Notice of effectiveness
12:15am
424B3
286ygps2kb0u3h3
27 Dec 21
Prospectus supplement
5:01pm
CORRESP
4aeec1f udjzc
22 Dec 21
Correspondence with SEC
12:00am
UPLOAD
m24v154mb
21 Dec 21
Letter from SEC
12:00am
8-K
6m41pp z1r9
24 Nov 21
Seelos Therapeutics Announces Acquisition of an Exclusive License of iX Biopharma’s Proprietary Wafer-Based Delivery Platform for Sublingual Ketamine
8:20am
8-K
ge87mxeq uzp4b3
24 Nov 21
Entry into a Material Definitive Agreement
7:27am
8-K
a5zw 5qpqx
25 Oct 21
Seelos Therapeutics Presents a Poster on SLS-002 (Intranasal Racemic Ketamine) at the 2021 IASR/AFSP International Summit on Suicide Research
2:03pm
8-K
ma5i edfk
2 Sep 21
Seelos Therapeutics Announces Senior Management Appointments
4:01pm
8-K
n0sma9am
17 Jun 21
Termination of a Material Definitive Agreement
4:14pm
8-K
u8c73zd9w2 86vm68m
24 May 21
Seelos Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
4:15pm
8-K
8vy h734qnp
21 May 21
Material Modifications to Rights of Security Holders
4:29pm
8-K
nzrx73m54 3kr7pf2v
21 May 21
Seelos Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock
12:00am
424B5
uyhb8x3tibovfkf
21 May 21
Prospectus supplement for primary offering
12:00am
424B5
isny6qrgye9x6p
19 May 21
Prospectus supplement for primary offering
4:08pm